Company: RPTX
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030405
Chunk: 171

Company: Repare Therapeutics Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 8
Chunk 171
---

    )

    Cash Flows From Investing Activities:

    Purchase of property and equipment

    —

    (1,938
    )

    Proceeds from maturities of marketable securities

    182,823

    259,000

    Purchase of marketable securities

    (133,355
    )

    (179,021
    )

    Net cash provided by investing activities

    49,468

    78,041

    Cash Flows From Financing Activities:

    Proceeds from exercise of stock options

    17

    153

    Proceeds from issuance of common shares under the 2020 Employee Share Purchase Plan

    525

    689

    Net cash provided by financing activities

    542

    842

    Effect of exchange rate fluctuations on cash held

    (116
    )

    22

    Net Decrease In Cash And Cash Equivalents

    (26,551
    )

    (48,253
    )

    Cash and cash equivalents cash at beginning of year

    111,268

    159,521

    Cash and cash equivalents at end of year
     
    $
    84,717

    $
    111,268

    .

    Supplemental Disclosure Of Cash Flow Information:

    Cash interest received
     
    $
    2,380

    $
    3,089

    Cash taxes paid, net
     
    $
    139

    $
    4,945

    Right-of-use assets obtained in exchange for new operating lease liability
     
    $
    957

    $
    149

The accompanying notes are an integral part of these consolidated financial statements 

105

REPARE THERAPEUTICS INC.